Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study-March 2024-www.financetom.com

Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study

Aug 13, 2025 5:52 AM

08:17 AM EDT, 08/13/2025 (MT Newswires) -- Ocugen ( OCGN ) said Wednesday that the European Medicines Agency's Committee for Medicinal Products for Human Use provided acceptability for a phase 2/3 trial of OCU410ST to submit for a marketing authorization application.

The company said the acceptance is based on results from its phase 1 GARDian trial. It added that the trial is intended to study its modifier gene therapy of OCU410ST to treat Stargardt disease, a genetic eye condition.

Shares of the company fell 1% in recent premarket activity Wednesday.

Previous page： Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing Next page： Radio Free Asia to suspend news operations amid government shutdown

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Kymera Therapeutics Insider Sold Shares Worth $1,829,737, According to a Recent SEC Filing

Oct 29, 2025

05:22 PM EDT, 10/29/2025 (MT Newswires) -- Nello Mainolfi, Director, Chief Executive Officer, on October 29, 2025, sold 30,000 shares in Kymera Therapeutics ( KYMR ) for $1,829,737. Following the Form 4 filing with the SEC, Mainolfi has control over a total of 660,482 common shares of the company, with 660,482 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1815442/000119312525256673/xslF345X05/ownership.xml ...

Radio Free Asia to suspend news operations amid government shutdown

Oct 29, 2025

WASHINGTON (Reuters) -Radio Free Asia said on Wednesday it was suspending its editorial operations amid funding uncertainty as the U.S. federal government shutdown edges toward its one-month mark. The broadcaster, which is funded by the U.S. government, said it would halt all production of news content on Friday due to the shutdown and a delay in receiving funding for its...

Teladoc Health Posts Mixed Results For Q3, Shares Move Lower

Oct 29, 2025

Teladoc Health Inc ( TDOC ) reported financial results for the third quarter after the closing bell on Wednesday. Here’s a rundown of the telehealth company’s report. Q3 Highlights: Teladoc reported third-quarter revenue of $626.44 million, beating analyst estimates of $625.91 million. The telehealth company reported a third-quarter adjusted loss of 20 cents per share, beating estimates for a loss of 27...

Exxon Mobil names Gregory Garland to board of directors

Oct 29, 2025

(Reuters) -Oil major Exxon Mobil ( XOM ) said on Wednesday it has named industry veteran Gregory Garland to its board of directors, effective November 3. Garland brings more than a decade of experience and served as the CEO of U.S. refiner Phillips 66 from 2012 to 2022 and as the top boss of Chevron Phillips Chemical Company from 2008...